Trial Profile

A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olaparib (Primary)
Indications Advanced breast cancer; Inflammatory breast cancer; Triple negative breast cancer
Focus Adverse reactions
Acronyms RadioPARP
Sponsors AstraZeneca

27 Nov 2023 Status changed from active, no longer recruiting to completed.
07 Jun 2022 Final results assessing appropriate dosing and safety profile with a follow-up of 34months presented at the 58th Annual Meeting of the American Society of Clinical Oncology
15 Nov 2021 Results reporting 1-year follow-up toxicity profile of combination of Olaparib with radiotherapy in triple negative breast cancer patients published in the International Journal of Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com